• NIH: Dietary Approach Significantly Lowers Blood Pressure

• NIH: New High Blood Pressure Guidelines Released by the NHLBI

• NIH: The DASH Diet

• AHCPR: Benefits of blood pressure medication may not outweigh risks for some patients

• FDA: WARNING LABELING CHANGES FOR NEW HEART DRUG POSICOR

• FDA Warning Information Concerning the Use of POSICOR

• FDA: BACKGROUND: POSICOR LABELING CHANGES

• FDA Consumer: Lessening the Pressure: Array of Drugs Tames Hypertension - Jul 99

• FDA Consumer: Treating High Blood Pressure - Jul 99

• SOLVAY PHARMACEUTICALS, INC. INTRODUCES ACEON TABLETS TO U.S. MARKET - 6 Oct 99

Medical Sciences Bulletin

• ACE Inhibitor Trandolapril Approved for Hypertension
• ACE Inhibitors and Birth Defects
• Another Look at Calcium Channel Blockers
• Atacand for the Management of Hypertension - Oct 98
• Calcium Antagonists and ACE Inhibitors Overused in Hypertension
• Calcium Channel Blockers and Cancer
• Calcium Channel Blockers and Increased Risk of Myocardial Infarction
• Calcium-channel Blockers Under Fire
• Carvedilol Approved for Hypertension
• Do We Need More Antihypertensive Agents?
• Enalapril-Felodipine ER for Hypertension
• Fenoldopan for the Management of Acute Hypertensive Crisis
• Focus On... ACE Inhibitors in the 90s
• Focus On. . . Calcium blockers and the heart
• Focus On... The "Statins" and the Heart
• Irbesartan Approved for Hypertension
• Losartan-induced Angioedema
• Low-dose Aspirin Safe During Pregnancy
• Mibefradil for Hypertension and Angina Pectoris
• Nisoldipine approved for hypertension
• Valsartan for Hypertension
• Verapamil COER-24 for angina and hypertension

PNN Pharmacotherapy Line

• Bristol-Myers Squibb Contradicts FDA
• Calcium-Channel Blocker Linked to More Deaths
• CCBs: No Link to Cancer
• CCBs: Proarrhythmic?
• Hypertension: Importance of Heredity Underscored
• Hypertension: Years of Lost Life and Work - Jul 98
• More Data on Problems with Short-Acting CCBs
• Nitrendipine Shows Positive Results for Systolic BP
• Perindopril Approved for Hypertension Treatment - Oct 99
• Racial Differences with Antihypertensive Drugs
• Studies Explore Abnormal Glucose Metabolism - Jul 98
• Use of NSAIDs Questioned in High-Risk Patients
• Tight Blood Pressure Control Aids Diabetics - Sep 98
• Warning Issued for Two Risks with Mibefradil
• Weight, Salt Reduction Effective in Hypertension

• American Society of Hypertension, 1996
  • Adrenergic and metabolic differences in white-coat hypertension and essential hypertension during physical and mental stress.
  • African Caribbean and IndoAsian Migration and Cardiovascular Disease in Britain.
  • Age, Race and Gender: What have we learned from recent studies about treating hypertensives?
  • The ALLHAT Trial: an interim update on recruitment and baseline characteristics
  • The American Society of Hypertension/Hoechst Marion Roussel Young Scholar's Award Lectures
  • ASH special lecture: molecular genetic Mechanisms of obesity.
  • Cardiovascular Safety of Long-Acting Calcium Channel Blockers
  • Chronobiology: Its role in hypertension
  • A Clinical Trial To Improve HBP Care In Young Urban African American Men.
  • Defining hypertension in American Indians.
  • Diet Improves Quality of Life (QOL) In Patients With Generalized Cardiovascular Metabolic Disease (GCMD)
  • Dietary fiber supplementation and blood pressure reduction: a meta-analysis of controlled clinical trials
  • Discrepancies between mean office and ambulatory blood pressures in primary care
  • Effects of an acute exposure to discotheque music on ambulatory blood pressure monitoring in normotensive subjects.
  • Effects of Aging on the Cardiovascular System
  • Estrogen and cardiovascular disease: an overview
  • Head-to-head heart drug study designed to settle treatment controversy
  • Hypertension, Race and End-Stage Renal Disease: a 25-year experience
  • Increased plasma endothelin-1 levels in diabetic retinopathy.
  • Interaction of coronary artery disease, left ventricular hypertrophy, cardiac arrhythmias and cardiac risk factors in elderly African-American veterans.
  • Is there a relationship between ECG and echocardiography for left ventricular mass in patients with mild hypertension?
  • Managing Hypertension in Managed Care: The diabetes model from the Group Health Cooperative of Puget Sound.
  • The Mayo Clinic/John Deere health care experience in hypertension management.
  • Mineral water and blood pressure: a randomized double-blind crossover trial in the elderly.
  • The natural history of blood pressure in children.
  • New directions in angiotensin II signaling.
  • New Trends in Combination Antihypertensive Therapy
  • Polycystic Kidney Disease
  • Pregnancy and Hypertension: Preeclampsia vs Chronic Hypertension
  • The Prognostic Significance of Blood Pressure Variability in Essential Hypertension
  • Regional variation in cardiovascular mortality in the United States.
  • Renal Disease and Renal Artery Stenosis in the Elderly
  • The role of renin uptake in vascular function.
  • The Safety of Heart Rate-Lowering Calcium Channel Blockers
  • Short-Term Transdermal Scopolamine Treatment Increases Cardiovagal Activity And Reduces Blood Pressure in Stage 1-2 Hypertensive Patients.
  • Steptreadmill exercise training and the reduction of resting blood pressure in women with hypertension.
  • Teaching about Hypertension in Medical Schools.
  • Treating Chronic Hypertension in Pregnancy
  • Treating hypertension in the elderly: maintaining quality of life
  • Waist-to-Hip Ratio Correlates with Left Ventricular Mass and Plasma Renin Activity in Hypertensives.

• American Society of Hypertension, 1995
  • AMERICAN SOCIETY OF HYPERTENSION POSTER SESSION - Day 2
  • AMERICAN SOCIETY OF HYPERTENSION POSTER SESSION - Day 3
  • AMERICAN SOCIETY OF HYPERTENSION POSTER SESSION - Day 4
  • ANGIOTENSIN ANTAGONISTS AND RENIN INHIBITORS: A REAL STEP FORWARD
  • ANGIOTENSIN II: IMPACT OF BASIC SCIENCES ON CLINICAL PRACTICE
  • CLINICAL HYPERTENSION: From Clinical Trials to Clinical Practice
  • CLINICAL TRIALS: NEW FINDINGS FROM COMPLETED STUDIES AND FUTURE DIRECTIONS
  • DEBATE: DIURETICS - THE QUESTIONS CONTINUE
  • DEBATE: SHOULD DIHYDROPYRIDINES BE USED FOR FIRST-LINE TREATMENT OF HYPERTENSION?
  • DISCUSSION OF HOME AMBULATORY BLOOD PRESSURE MONITORING
  • EFFECT OF ACE INHIBITION ON PROGRESSION OF CARDIOVASCULAR DISEASES
  • HOW LOW SHOULD BLOOD PRESSURE BE?
  • HYPERTENSION (ASH/GOVERNMENT/ACADEMIA/INDUSTRY SYMPOSIUM)
  • HYPERTENSION IN SPECIAL POPULATIONS
  • HYPERTENSION MANAGEMENT in PATIENTS WITH DIVERSE PRESENTATIONS
  • METABOLIC ISSUES AND TREATMENT OF HYPERTENSION
  • OUTCOMES, HYPERTENSIVE DISEASE, AND ITS TREATMENT: A Prospective Study of Disease Progression in Patients with Atherosclerotic Renal Artery Stenosis
  • OUTCOMES, HYPERTENSIVE DISEASE, AND ITS TREATMENT: Isolated Systolic Hypertension (ISH): The Most Powerful Risk Factor of Stroke and MI
  • OUTCOMES, HYPERTENSIVE DISEASE, AND ITS TREATMENT: Urinary Albumin Excretion: A Stronger Predictor of Cardiovascular Risk than Blood Pressure and Serum Cholesterol
  • PATIENT EVALUATION: Ambulatory Monitoring of Blood Pressure in Evaluating Hypertensive Patients
  • PATIENT EVALUATION: Is the Recommended Workup Adequate?
  • SOCIOECONOMIC DETERMINANTS OF HYPERTENSION AND ITS CONTROL: STRESS AND HYPERTENSION
  • SOCIOECONOMIC DETERMINANTS OF HYPERTENSION AND ITS CONTROL: Data from the Third National Health and Nutrition Examination Survey
  • SOCIOECONOMIC DETERMINANTS OF HYPERTENSION AND ITS CONTROL: Inner City Minorities and Hypertension
  • SUNRISE SEMINAR SERIES INDIVIDUALIZATION OF TREATMENT FOR HYPERTENSION in 1995
  • SUNRISE SEMINAR SERIES MANAGEMENT OF HYPERTENSION IN MINORITIES: AFRICAN-AMERICANS, HISPANICS
  • SUNRISE SEMINAR SERIES: COMPLIANCE TO THERAPY
  • THE EMERGING ROLE OF CHRONOTHERAPEUTICS IN MANAGING HYPERTENSION
  • THE PATHOBIOLOGY OF ATHEROSCLEROSIS: From Fatty Streak to Myocardial Infarction
  • THE PATHOBIOLOGY OF ATHEROSCLEROSIS: Modification of LDL Structure in Relation to Atherosclerosis
  • THE ROLE OF SOCIOECONOMIC STATUS IN HYPERTENSION
  • UNRESOLVED ISSUES IN THE TREATMENT OF HYPERTENSION

Discussion Archives

Sorry, no discussions available at this time.

Drugs for Treating Hypertension

• acebutolol (Sectral)
• amlodipine (Norvasc, Lotrel )
• atenolol (Tenormin)
• benazepril (Lotensin)
• captopril (Capoten)
• carvedilol (Coreg)
• chlorothiazide (Diuril)
• chlorthalidone (Hygroton, Combipres, Tenoretic)
• diltiazem (Cardizem)
• doxazosin (Cardura)
• enalapril (Vasotec)
• enalapril-felodipine ER (Lexxel)
• fenoldopam (Corlopam)
• fosinopril (Monopril)
• furosemide (Lasix)
• hydrochlorothiazide (Esidrex, Hydrodiuril)
• irbesartan (Avapro)
• labetalol (Normodyne, Trandate)
• lisinopril (Prinivil, Zestril)
• losartan (Cozaar)
• methyldopa (Aldomet )
• metoprolol (Lopressor)
• mibefradil (Posicor)
• nifedipine (Procardia XL)
• nisoldipine (Sular)
• propranolol (Inderal)
• omapatrilat (Lantus)
• quinapril (Accupril)
• ramipril (Altace)
• spironolactone (Aldactone)
• trandolapril (Mavik)
• valsartan (Diovan)
• verapamil (Calan, Isoptin)

Newsgroups

sci.med.cardiology

Mailing Lists

To subscribe to the mailing list in the first column, send a message to the email address in the second column (or to the alternate if given) containing the command in the second column just below the email address. Note that Firstname Lastname is your real name, such as John Doe. The listserv software will use the email address in your message header for your subscription. If you have trouble sending email to the listserv, or if you receive no response, then you will need the help of someone at your site.

Name Description	Subscription Address Subscription Message
CARDIO-CONSULT CARDIO-CONSULT facilitates peer-to-peer communication between members and recognized experts and leaders in cardiovascular medicine. Participants are encouraged to share clinical experiences with the group. These experiences should be submitted as brief case reports, including the relevant background data.	listserv@shrsys.hslc.org subscribe CARDIO-CONSULT Firstname Lastname

Web Sites

American Society of Hypertension

To better understand, disseminate, and evaluate the vast accumulation of data on hypertension, and to provide a separate forum for those involved in the study or management of high blood pressure, 17 world-famous clinicians and scientists met in 1985 and formed The American Society of Hypertension (ASH), the largest US organization devoted exclusively to hypertension and related cardiovascular diseases.

Since that time, ASH has become a scientific organization on the cutting edge of education, research and treatment strategies, and has earned the respect of clinicians, scientists, industry and government agencies.

ASH's members now number over 3,000. Ninety-five percent of ASH's membership has a Ph.D., M.D. or other advanced degree.

National Heart, Lung, and Blood Institute of the National Institutes of Health

Last modified on 10/25/99 12:24:48 PM. © 1999 Mediconsult.com, Inc. All rights reserved. As seen on PharmInfoNet ()

Additional Drug Information